Exosens (EXENS) AGM 2026 summary

Opening remarks and agenda

• Session opened by the Chairman of the Board, Jean-Hubert Vial, with a detailed agenda covering group presentation, activity review, financial results, governance, remuneration, auditor reports, Q&A, and voting on resolutions.

Financial performance review

• 2025 revenue reached €468.2M, up 12.7% at constant scope and currency, with adjusted EBITDA of €151.6M (+26.6%).

• Adjusted EBITDA margin improved to 32.4%, and free cash flow was €57.3M, with a cash conversion ratio of 73.6%.

• Net result from continuing operations was €70.2M, reflecting strong profitability.

• Financial leverage stood at 1.3x, with €68.5M in cash and an undrawn €100M credit facility.

• 2026 guidance: revenue €520–540M, adjusted EBITDA €168–178M, with mid-term organic growth targets up to 15% annually.

Board and executive committee updates

• Board comprised 8 members (4 independent, 3 women), average age 53.4, with 98.1% attendance.

• Mandates of Michel Mariton and Brigitte Geny proposed for renewal for four years.

• Audit, nomination/remuneration, and CSR committees reported high independence and participation rates.